Grandfield & Dodd’s Iovance Biotherapeutics IOVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$926K Sell
62,500
-20
-0% -$143 0.05% 117
2026
Q2
$260K Buy
62,520
+2,340
+4% +$8.89K 0.01% 199
2026
Q1
$211K Sell
60,180
-5,750
-9% -$18.4K 0.01% 200
2025
Q4
$180K Sell
65,930
-11,895
-15% -$27.5K 0.01% 206
2025
Q3
$169K Sell
77,825
-13,250
-15% -$31.3K 0.01% 210
2025
Q2
$157K Buy
91,075
+100
+0.1% +$249 0.01% 211
2025
Q1
$303K Buy
90,975
+35,260
+63% +$182K 0.02% 169
2024
Q4
$412K Buy
55,715
+25,645
+85% +$238K 0.03% 151
2024
Q3
$282K Buy
+30,070
New +$285K 0.02% 182

Other funds holding IOVA

Grandfield & Dodd's IOVA Position: Q3 2026 in Review

Grandfield & Dodd reduced its Iovance Biotherapeutics (IOVA) stake by 0.03% in Q3 2026, selling an estimated $143 and leaving 62,500 shares worth $926K. The position accounts for 0.05% of the portfolio, ranked #117.

Grandfield & Dodd first reported a position in IOVA in Q3 2024 and has held it in 9 quarters since. 334 funds tracked by Wall St. Rank hold IOVA as of Q3 2026.

  • Grandfield & Dodd held 62,500 shares of Iovance Biotherapeutics worth $926K as of Q3 2026.
  • Grandfield & Dodd sold 20 Iovance Biotherapeutics shares in Q3 2026, an estimated $143.
  • Iovance Biotherapeutics made up 0.05% of Grandfield & Dodd's portfolio in Q3 2026, its #117 holding.
  • Grandfield & Dodd first reported a position in Iovance Biotherapeutics in Q3 2024 and has held it in 9 quarters since.
  • 334 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2026.

Based on Grandfield & Dodd's 13F filing for Q3 2026, filed 29 Oct 2026.